Literature DB >> 25209853

SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype.

Kathryn J Peall1, Manju A Kurian, Mark Wardle, Adrian J Waite, Tammy Hedderly, Jean-Pierre Lin, Martin Smith, Alan Whone, Hardev Pall, Cathy White, Andrew Lux, Philip E Jardine, Bryan Lynch, George Kirov, Sean O'Riordan, Michael Samuel, Timothy Lynch, Mary D King, Patrick F Chinnery, Thomas T Warner, Derek J Blake, Michael J Owen, Huw R Morris.   

Abstract

Myoclonus dystonia syndrome (MDS) is a young-onset movement disorder. A proportion of cases are due to mutations in the maternally imprinted SGCE gene. We assembled the largest cohort of MDS patients to date, and determined the frequency and type of SGCE mutations. The aim was to establish the motor phenotype in mutation carriers and utility of current diagnostic criteria. Eighty-nine probands with clinical features compatible with MDS were recruited from the UK and Ireland. Patients were phenotypically classified as "definite", "probable" or "possible" MDS according to previous guidelines. SGCE was analyzed using direct sequencing and copy number variant analysis. In those where no mutation was found, DYT1 (GAG deletion), GCH1, THAP1 and NKX2.1 genes were also sequenced. Nineteen (21.3%) probands had an SGCE mutation. Three patterns of motor symptoms emerged: (1) early childhood onset upper body myoclonus and dystonia, (2) early childhood onset lower limb dystonia, progressing later to more pronounced myoclonus and upper body involvement, and (3) later childhood onset upper body myoclonus and dystonia with evident cervical involvement. Five probands had large contiguous gene deletions ranging from 0.7 to 2.3 Mb in size with distinctive clinical features, including short stature, joint laxity and microcephaly. Our data confirms that SGCE mutations are most commonly identified in MDS patients with (1) age at onset ≤10 years and (2) predominant upper body involvement of a pure myoclonus-dystonia. Cases with whole SGCE gene deletions had additional clinical characteristics, which are not always predicted by deletion size or gene involvement.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25209853      PMCID: PMC4495322          DOI: 10.1007/s00415-014-7488-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  45 in total

1.  Myoclonus-dystonia: significance of large SGCE deletions.

Authors:  A Grünewald; A Djarmati; K Lohmann-Hedrich; K Farrell; J A Zeller; N Allert; F Papengut; B Petersen; V Fung; C M Sue; D O'Sullivan; N Mahant; A Kupsch; R S Chuang; K Wiegers; H Pawlack; J Hagenah; L J Ozelius; U Stephani; R Schuit; A E Lang; J Volkmann; A Münchau; C Klein
Journal:  Hum Mutat       Date:  2008-02       Impact factor: 4.878

2.  The epsilon-sarcoglycan gene in myoclonic syndromes.

Authors:  E M Valente; M J Edwards; P Mir; A DiGiorgio; S Salvi; M Davis; N Russo; M Bozi; H-T Kim; G Pennisi; N Quinn; B Dallapiccola; K P Bhatia
Journal:  Neurology       Date:  2005-02-22       Impact factor: 9.910

3.  Myoclonus dystonia plus syndrome due to a novel 7q21 microdeletion.

Authors:  Pascale Saugier-Veber; Diane Doummar; Marie-Anne Barthez; Virginie Czernecki; Nathalie Drouot; Emmanuelle Apartis; Lydie Bürglen; Thierry Frebourg; Emmanuel Roze
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

4.  Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome.

Authors:  T Trottenberg; W Meissner; C Kabus; G Arnold; T Funk; K M Einhaupl; A Kupsch
Journal:  Mov Disord       Date:  2001-07       Impact factor: 10.338

5.  Phenotype-genotype correlation in Dutch patients with myoclonus-dystonia.

Authors:  M C F Gerrits; E M J Foncke; R de Haan; K Hedrich; Y L C van de Leemput; F Baas; L J Ozelius; J D Speelman; C Klein; M A J Tijssen
Journal:  Neurology       Date:  2006-03-14       Impact factor: 9.910

6.  Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype.

Authors:  Friedrich Asmus; Lena Elisabeth Hjermind; Erik Dupont; Janine Wagenstaller; Edda Haberlandt; Marita Munz; Tim M Strom; Thomas Gasser
Journal:  Brain       Date:  2007-10       Impact factor: 13.501

7.  Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with epsilon-sarcoglycan mutations.

Authors:  Deborah Raymond; Rachel Saunders-Pullman; Patricia de Carvalho Aguiar; Birgitt Schule; Norman Kock; Jennifer Friedman; Juliette Harris; Blair Ford; Steven Frucht; Gary A Heiman; Danna Jennings; Dana Doheny; Mitchell F Brin; Deborah de Leon Brin; Trisha Multhaupt-Buell; Anthony E Lang; Roger Kurlan; Christine Klein; Laurie Ozelius; Susan Bressman
Journal:  Mov Disord       Date:  2008-03-15       Impact factor: 10.338

Review 8.  Myoclonus-dystonia: an update.

Authors:  Kiyoka Kinugawa; Marie Vidailhet; Fabienne Clot; Emmanuelle Apartis; David Grabli; Emmanuel Roze
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

9.  Phenotypic features of myoclonus-dystonia in three kindreds.

Authors:  D O Doheny; M F Brin; C E Morrison; C J Smith; R H Walker; S Abbasi; B Müller; J Garrels; L Liu; P De Carvalho Aguiar; K Schilling; P Kramer; D De Leon; D Raymond; R Saunders-Pullman; C Klein; S B Bressman; B Schmand; M A J Tijssen; L J Ozelius; J M Silverman
Journal:  Neurology       Date:  2002-10-22       Impact factor: 9.910

10.  Myoclonus in a patient with a deletion of the epsilon-sarcoglycan locus on chromosome 7q21.

Authors:  Ralph J DeBerardinis; Danielle Conforto; Karen Russell; Jennifer Kaplan; Peter R Kollros; Elaine H Zackai; Beverly S Emanuel
Journal:  Am J Med Genet A       Date:  2003-08-15       Impact factor: 2.802

View more
  25 in total

Review 1.  Principles of Medical and Surgical Treatment of Cerebral Palsy.

Authors:  Eric M Chin; Hilary E Gwynn; Shenandoah Robinson; Alexander H Hoon
Journal:  Neurol Clin       Date:  2020-05       Impact factor: 3.806

2.  Network Analysis of Depression-Related Transcriptomic Profiles.

Authors:  Xiao Miao; Bin Fan; Rongqun Li; Shaoping Zhang; Honghuang Lin
Journal:  Neuromolecular Med       Date:  2019-03-01       Impact factor: 3.843

Review 3.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

Review 4.  Update on the Genetics of Dystonia.

Authors:  Katja Lohmann; Christine Klein
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

5.  Collection of developmental history in the evaluation of schizophrenia spectrum disorders.

Authors:  Angela M Reiersen
Journal:  Scand J Child Adolesc Psychiatr Psychol       Date:  2016

Review 6.  ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder.

Authors:  Nirosen Vijiaratnam; Kailash P Bhatia; Anthony E Lang; Wendy H Raskind; Alberto J Espay
Journal:  Mov Disord Clin Pract       Date:  2019-08-19

7.  Role of major and brain-specific Sgce isoforms in the pathogenesis of myoclonus-dystonia syndrome.

Authors:  Jianfeng Xiao; Satya R Vemula; Yi Xue; Mohammad M Khan; Francesca A Carlisle; Adrian J Waite; Derek J Blake; Ioannis Dragatsis; Yu Zhao; Mark S LeDoux
Journal:  Neurobiol Dis       Date:  2016-11-24       Impact factor: 5.996

8.  A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia.

Authors:  Niccolo E Mencacci; Ignacio Rubio-Agusti; Anselm Zdebik; Friedrich Asmus; Marthe H R Ludtmann; Mina Ryten; Vincent Plagnol; Ann-Kathrin Hauser; Sara Bandres-Ciga; Conceição Bettencourt; Paola Forabosco; Deborah Hughes; Marc M P Soutar; Kathryn Peall; Huw R Morris; Daniah Trabzuni; Mehmet Tekman; Horia C Stanescu; Robert Kleta; Miryam Carecchio; Giovanna Zorzi; Nardo Nardocci; Barbara Garavaglia; Ebba Lohmann; Anne Weissbach; Christine Klein; John Hardy; Alan M Pittman; Thomas Foltynie; Andrey Y Abramov; Thomas Gasser; Kailash P Bhatia; Nicholas W Wood
Journal:  Am J Hum Genet       Date:  2015-05-14       Impact factor: 11.025

Review 9.  ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene.

Authors:  Ana Cazurro-Gutiérrez; Anna Marcé-Grau; Marta Correa-Vela; Ainara Salazar; María I Vanegas; Alfons Macaya; Àlex Bayés; Belén Pérez-Dueñas
Journal:  Mol Neurobiol       Date:  2021-04-22       Impact factor: 5.590

10.  Mutation in ε-Sarcoglycan Induces a Myoclonus-Dystonia Syndrome-Like Movement Disorder in Mice.

Authors:  Jiao Li; Yiqiong Liu; Qin Li; Xiaolin Huang; Dingxi Zhou; Hanjian Xu; Feng Zhao; Xiaoxiao Mi; Ruoxu Wang; Fan Jia; Fuqiang Xu; Jing Yang; Dong Liu; Xuliang Deng; Yan Zhang
Journal:  Neurosci Bull       Date:  2020-12-23       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.